TAGLN2 and cancer: Transcriptional and translational upregulation of transgelin-2 has been described for many cancers, including colorectal, gastric, pancreatic, esophageal, prostate, lung, hepatic, renal, bladder, and oral cancers (Yang et al., 2007; Huang et al., 2008; Rho et al., 2009; Zhang et al., 2010; Leung et al., 2011; Yoshino et al., 2011; Kawakami et al., 2012; Lin et al., 2013; Kawahara et al., 2016), in addition to meningiomas, head and neck squamous cell carcinoma (SCC), lymphoma, and leukemia (Gez et al., 2007; Nohata et al., 2011b; Sharma et al., 2015).